Objective assessment of fesoterodine for overactive bladder with benign prostatic hyperplasia
Not Applicable
- Conditions
- Overactive bladder associated with benign prostatic hyperplasia
- Registration Number
- JPRN-UMIN000010296
- Lead Sponsor
- Dept. of Urology, Kyoto University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Male
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1) Post-void residual≥50ml 2) Urinary retention 3) Prostate cancer, neurogenic bladder, urethral stricture, chronic prostatitis, urinary infection, urinary tract calculi, interstitial cystitis 4) Patients who are contraindicated for fesoterodine administration 5) Within 2 weeks before entry, administration of contraindicated agents or treatments
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change of maximal bladder capacity and detrusor pressure on voiding by fesoterodine administration
- Secondary Outcome Measures
Name Time Method 1) Changes of other parameters of urodynamic studies 2) Changes of parameters of questionnaires 3) Changes of parameters of frequency-volume charts 4) Safety 5) Ratio of increase of fesoterodine dose